Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
Novo Nordisk has a huge opportunity in GLP-1 weight-loss drugs, but it has to prove it can use that success to build for the future.
Overview
Novo Nordisk (NYSE: NVO) has seen both sides of the emotional swings investors often experience. Enthusiastic investors pushed its stock higher by more than 200% in less than three years. And less than three years after that peak, pessimistic investors have crushed the shares by more than 70%. The stock is now below where it started five years ago.
There are very real reasons for investors to be worried about Novo Nordisk. However, if you are a long-term investor, there are also reasons for optimism. This deep drawdown could very well be a generational opportunity to buy the stock, if you have the stomach for it.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.